Balloon Dilation of Eustachian Tube

Date of Origin: 1/2021  Last Review Date: 1/27/2021  Effective Date: 4/15/2021

Dates Reviewed: 1/27/2021

Developed By: Medical Necessity Criteria Committee

I. Description

Eustachian tube dysfunction (ETD) is a common medical condition affecting approximately 1% of the adult population. Both children and adults are affected, and may manifest as muffled hearing, aural fullness, pain, ear popping, tinnitus, or problems with balance. Long term dysfunction can potentially lead to serious consequences such as hearing loss, cholesteatoma, and chronic suppurative otitis media. Patients suffering from ET dysfunction typically present with complaints of hearing loss or sensation of pressure or plugged ear, which can lead to impaired quality of life. The eustachian tube (ET) is a complex ossecartilaginous connection between protympanum and the nasopharynx. The ET protects the middle ear from sources of disease, to ventilate the middle ear, and to help drain secretions away from the middle ear. ETD is the inability of the ET to maintain adequate performance of these functions.

Balloon dilation of the eustachian tube is a minimally invasive method for treating chronic obstructive eustachian tube dysfunction. The minimally invasive intervention aims to increase the patency of the cartilaginous part of eustachian tube and reduce inflammation. The technique involves in which a small tube containing a balloon is inserted into the nose and threaded into the eustachian tube. The tiny balloon is then inflated, which opens the tube. The balloon is left in place for a couple of minutes, deflated, and removed.

II. Criteria: CWQI HCS-0306

A. OHSU Health Services considers balloon dilation of eustachian tube for treatment of chronic obstructive eustachian tube dysfunction in adults 18 and older medically necessary when ALL of the following requirements are met;

   a. Patient has had symptoms of obstructive eustachian tube and/or hearing loss for three months or longer in one or both years that significantly affects quality of life or impairs function and meets ALL of the following;

      i. Presence of aural fullness and pressure
      ii. Patient is NOT diagnosed with patulous ETD (Eustachian tube stays open)
      iii. Other causes of aural fullness such a temporomandibular joint disorder, extrinsic obstruction of the eustachian tube, superior semicircular canal dehiscence, endolymphatic hydrops etc have been ruled out
iv. Patient symptoms are continuous rather than episodic (e.g. symptoms occur only in response to barochallenge such as pressure changes while flying)

v. Patient has not previously had balloon dilation of eustachian tube procedure (BDET)

b. Documentation of completed comprehensive diagnostic assessment with ALL of the following findings;
   i. Abnormal tympanogram (Type B or C)
   ii. Abnormal tympanic membrane (retracted membrane, effusion, perforation or any other abnormality identified following otoscopy exam)

   a. Documentation of completed comprehensive diagnostic assessment with ALL of the following findings;
   i. Abnormal tympanogram (Type B or C)
   ii. Abnormal tympanic membrane (retracted membrane, effusion, perforation or any other abnormality identified following otoscopy exam)

   c. If applicable, failure to respond to medical management of co-occuring conditions which include but not limited to;
      i. allergic rhinitis, rhinosinusitis, including 4-6 weeks of a nasal steroid if indicated
      ii. laryngopharyngeal reflux; with proton pump inhibitor or antacid treatment

   d. Reversibility of patient’s eustachian tube dysfunction has been demonstrated

B. Balloon dilation of the eustachian tube is considered NOT medically necessary for all other indications

C. Balloon dilation of the eustachian tube is considered investigational for repeat BDET and all other indications

D. Contraindications to balloon dilation of eustachian tubes
   a. Patients with extrinsic reversible or irreversible causes of eustachian tube dysfunction including but not limited to;
      i. Enlarged adenoid pads
      ii. History of radiation therapy to the nasopharynx
      iii. Craniofacial syndromes, including cleft palate spectrum
      iv. Nasopharyngeal mass
      v. Neoplasms causing extrinsic obstruction of the eustachian tube

   b. Patient with patulous eustachian tube dysfunction
   c. Patient with aural fullness but normal exam and tympanogram
   d. Patient with chronic and severe atelectatic ears (retracted tympanic membrane)

III. Information Submitted with the Request:

1. Chart notes with history documentation of a diagnosis and treatment of chronic eustachian tube dysfunction
2. Documentation of tympanic membrane abnormality and/or Tympanogram is abnormal

IV. CPT or HCPC codes covered:

<table>
<thead>
<tr>
<th>Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>69705</td>
<td>Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral</td>
</tr>
<tr>
<td>69706</td>
<td>Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral</td>
</tr>
<tr>
<td>69799</td>
<td>Unlisted procedure, middle ear</td>
</tr>
<tr>
<td>C9745</td>
<td>Nasal endoscopy, surgical; balloon dilation of eustachian tube</td>
</tr>
</tbody>
</table>
V. Annual Review History

<table>
<thead>
<tr>
<th>Review Date</th>
<th>Revisions</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/27/2021</td>
<td>New criteria</td>
<td>4/15/2021</td>
</tr>
<tr>
<td>3/2021</td>
<td>Following further review, updated requirement for patients experiencing obstructive eustachian tube dysfunction (OETD) in one or both ears for 3 months or longer</td>
<td></td>
</tr>
<tr>
<td>4/2021</td>
<td>CPT code C9745 added to criteria</td>
<td></td>
</tr>
</tbody>
</table>

VI. References


Appendix 1- Applicable Diagnosis Codes:

<table>
<thead>
<tr>
<th>Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

<table>
<thead>
<tr>
<th>Jurisdiction(s): 5, 8</th>
<th>NCD/LCD Document(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCD/LCD Document(s):

Medicare Part B Administrative Contractor (MAC) Jurisdictions

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
</tbody>
</table>